NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy (Q38631020)

4 September 2017

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy (English)

1 reference

4 September 2017

1 reference

Garnet Suck

1

1 reference

4 September 2017

Marcus Odendahl

2

1 reference

4 September 2017

Paulina Nowakowska

3

1 reference

4 September 2017

Christian Seidl

4

1 reference

4 September 2017

Winfried S Wels

5

1 reference

4 September 2017

Hans G Klingemann

6

1 reference

4 September 2017

Torsten Tonn

7

1 reference

4 September 2017

11 November 2015

1 reference

Cancer Immunology, Immunotherapy

4 September 2017

1 reference

4 September 2017

65

1 reference

4 September 2017

485-492

1 reference

4 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-015-1761-x

4 September 2017

0 references

cites work

Ex vivo expansion of natural killer cells for clinical applications.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Bringing natural killer cells to the clinic: ex vivo manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Signatures of human NK cell development and terminal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Protection from natural killer cell-mediated lysis by HLA-G expression on target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Oncolytic virotherapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Ex vivo purging of stem cell autografts using cytotoxic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Cellular therapy of cancer with natural killer cells-where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Shipping of therapeutic somatic cell products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Successful "in-flight" activation of natural killer cells during long-distance shipping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Constitutively polarized granules prime KHYG-1 NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

KHYG-1 and NK-92 represent different subtypes of LFA-1-mediated NK cell adhesiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Genetically modified T cells for the treatment of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Novel approaches using natural killer cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Therapeutic applications: natural killer cells in the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1761-X

10.1007/S00262-015-1761-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference